Avantor, Cytovance Biologics collaborate for plasmid DNA development
12 May 2022 | News
The collaboration will allow Avantor to provide global biopharma customers and contract manufacturing organisations access to plasmid DNA
Image Credit: Shutterstock
Avantor and Cytovance Biologics have entered into an agreement to manufacture research and GMP grade plasmids for biopharma customers. The collaboration extends Avantor's leadership in providing critical materials for next-generation vaccines and therapeutics focused on cell and gene therapy and mRNA drug manufacturing and expands Cytovance Biologics' global commercial reach.
The collaboration will allow Avantor to provide global biopharma customers and contract manufacturing organisations access to plasmid DNA and other mission-critical inputs used in research, clinical testing and manufacturing scale-up and commercialisation by leveraging Cytovance Biologics' plasmid cGMP manufacturing capabilities.
